Finanzen von Arcadia Biosciences Inc (RKDA)RKDAArcadia Biosciences Inc

Evaluating the bottom line, Arcadia Biosciences Inc maintains a gross margin of 43.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -34.37%, while the net margin is -434.23%. These profitability ratios, combined with a Return on Equity (ROE) of -430.93%, provide a clear picture of how effectively RKDA converts its operational activities into shareholder value.

In the context of the broader market, RKDA competes directly with industry leaders such as SNES and BIOX. With a market capitalization of $403.19K, it holds a significant position in the sector. When comparing efficiency, RKDA's gross margin of 43.73% stands against SNES's 73.64% and BIOX's 24.21%. Such benchmarking helps identify whether Arcadia Biosciences Inc is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 43.73% in Q2 2026, but has struggled with net income, showing losses in recent quarters, including a net income of -$6.27 million in Q2 2026.